

**ALL ORDERS MUST BE SIGNED, DATED AND TIMED BY PHYSICIAN**

**Allergies/Reactions:**

- |   |  |
|---|--|
| <input type="checkbox"/> Puyallup Infusion Center - Fax: 253-697-5066               | <input type="checkbox"/> Gig Harbor Infusion Services - Fax: 253-530-8069  |
| <input type="checkbox"/> Allenmore Ambulatory Infusion Services - Fax: 253-864-4052 | <input type="checkbox"/> DHEC Infusion Center - Fax: 509-755-5845          |
| <input type="checkbox"/> Auburn Infusion Services - Fax: 253-876-8282               | <input type="checkbox"/> North Spokane Infusion Center - Fax: 509-232-2531 |

**ORDERS WITH CHECK BOXES**

When an order is optional (those with check boxes), physicians are responsible for indicating a check mark in the box next to the order. Orders left unchecked will not be initiated.

**Teprotumumab (Tepezza)**

Patient Name: \_\_\_\_\_ Requested Date of Service: \_\_\_\_/\_\_\_\_/\_\_\_\_

Date of Birth: \_\_\_\_/\_\_\_\_/\_\_\_\_ Patient Phone Number: (\_\_\_\_) \_\_\_\_\_ - \_\_\_\_\_  May leave message

**Diagnosis:**

Thyroid eye disease

**ICD -10 Code:**

\_\_\_\_\_

**Required:** H&P with documentation to support above diagnosis including ICD-10 code and supporting labs and documentation

**\*\*If required documentation not received with order, scheduling of treatment will be delayed until complete information is available\*\***

**Baseline labs required:**

- Glucose fasting Date: \_\_\_\_/\_\_\_\_/\_\_\_\_ Results: \_\_\_\_\_

**Maintenance labs:**

Glucose fasting with each infusion

**IV Access:** Access and/or maintain IV site in accordance with MHS IV Therapy P&P; Peripheral IV Device Site Selection, Insertion, Maintenance, and Discontinuation; and Maintenance of Central Venous Catheters-Flushing, Dressing Changes and Removal.

**Treatment Regimen:**

Teprotumumab (Tepezza) every 21 days weight \_\_\_\_\_lb/kg

10 mg/kg \_\_\_\_\_mg x 1 over 90 minutes; followed by

20 mg/kg \_\_\_\_\_mg x 7 additional doses (1st dose over 90 minutes; remaining 6 infusions over 60 minutes if well tolerated)

**Vital Signs:** Check vital signs prior to and at completion of infusion.

Contact provider if systolic BP >180; diastolic BP >100; systolic BP <90; HR >110; temp >38C (100.4F)

**If hypersensitivity develops (fever, chills, hypotension, rigors, itching, rash, etc.):**

- Consult MultiCare Hypersensitivity guideline for treatment/management
- Notify provider of reaction, assessment and need for further orders"

**Code Status: Please note, patients will be considered FULL Code unless marked otherwise. If the patient has a POLST, advance directive or living will, please include a copy with the orders.**

Was consent obtained:  Yes  No (if yes, please send DOCUMENTATION of consent with order)

Provider Signature

Print Name

Date

Time

**Orders expire in 12 months\*\***

**Patient Identification - Always Attach Patient Label**

Name:

MRN #:

CSN #:

Age / Sex and Gender:

Pre-printed Order

**THYROID EYE DISEASE**

**MultiCare** 



60-0351-2 (5/23)